Drug Profile
Research programme: neurodegenerative disease therapeutics and diagnostics - Daiichi Sankyo/UCSF
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; University of California at San Francisco
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Neurodegenerative-disorders in USA
- 28 Jul 2018 No recent reports of development identified for research development in Neurodegenerative-disorders(Diagnosis) in USA
- 03 Apr 2014 Early research in Neurodegenerative disorders (diagnosis) in USA